Geographic AtrophyPhase 2CATALINANCT04465955
A Study of NGM621 in Participants With Geographic Atrophy
A Phase 2 study testing NGM621 in people with Geographic Atrophy, run by NGM Biopharmaceuticals, Inc at 65 sites in United States.
Trial summary
This is a multi-center evaluation of NGM621 in a randomized, double-masked, sham-controlled study in participants with Geographic Atrophy secondary to Age-related Macular Degeneration. Read more about this study
- Who is it for?
- Ages 55 years and older
- Conditions the study is for
- Geographic Atrophy
- What is being tested?
- NGM621
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 320 participants
- Where
- 65 sitesUnited States
- Study dates
- 22 Jul 2020to 16 Aug 2022
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 55 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male or female (non-pregnant, non-lactating) subjects ≥ 55 years
- Standard luminance BCVA score of 34 letters or better using ETDRS charts at the starting distance of 4 meters (approximately 20/200 Snellen equivalent or better) in study eye
- Clinical diagnosis of GA secondary to AMD:
- Total GA area must be ≥ 2.5 and ≤ 17.5 mm²
- If GA is multifocal, at least one focal lesion must be ≥ 1.25 mm² (0.5 DA), with the overall area of GA ≥ 2.5 and ≤ 17.5 mm²
- Well demarcated GA with no anatomical evidence of current or prior CNV in the study eye
Who cannot join
- Study Eye
- GA secondary to a condition other than AMD in either eye (e.g., monogenetic macular dystrophies like Stargardt disease, cone rod dystrophy, or toxic maculopathies)
- Any history of or active choroidal neovascularization (CNV)
- Both Eyes
- Any history of or active bacterial, viral, fungal, or parasitic infection in either eye in the 3 months prior to randomization
Trial locations and contacts
65 sites in 1 country.
65 sites in 1 country
United States65 sites
Texas Retina Associates
Arlington, Texas, 76012
Western Carolina Retinal Associates
Asheville, North Carolina, 18803
California Retina Consultants
Bakersfield, California, 93309
Thompson Sjaarda, PA
Baltimore, Maryland, 21204
Elman Retina Group PA
Baltimore, Maryland, 21237
Retina Vitreous Associates
Beverly Hills, California, 90211
Gailey Eye Clinic - Bloomington
Bloomington, Illinois, 61704
Ophthalmic Consultants of Boston
Boston, Massachusetts, 02114
Florida Eye Microsurgical Institute
Boynton Beach, Florida, 33426
Retinal Diagnostic Center
Campbell, California, 95008
Southeast Clinical Research
Charlotte, North Carolina, 28210
University of Virginia
Charlottesville, Virginia, 22903
University of Illinois
Chicago, Illinois, 60612
Sterling Research Group, Ltd.
Cincinnati, Ohio, 45219
Retina Associates of Cleveland
Cleveland, Ohio, 44122
The Cleveland Clinic
Cleveland, Ohio, 44195
Retina Consultants of Southern Colorado PC
Colorado Springs, Colorado, 80909
University of Miami
Coral Gables, Florida, 33146
Specialty Retina Center (Coral Springs)
Coral Springs, Florida, 33067
Retina Foundation of the Southwest
Dallas, Texas, 75231
Texas Retina Associates-Plano
Dallas, Texas, 75231
Duke University
Durham, North Carolina, 27705
The Retina Partners
Encino, California, 91436
Retina Group of Florida
Fort Lauderdale, Florida, 33308
National Ophthalmic Research Institute
Fort Myers, Florida, 33912
Retina Consultants of Orange County
Fullerton, California, 92835
Colorado Retina Associates PC
Golden, Colorado, 80401
Long Island Vitreoretinal Consultants
Great Neck, New York, 11021
Retina Consultants of Houston
Houston, Texas, 77030
Raj K. Maturi, MD, PC
Indianapolis, Indiana, 46290
Eye Care Specialists
Kingston, Pennsylvania, 18704
Southeastern Retina Associates
Knoxville, Tennessee, 37922
University Retina and Macula Associates, PC
Lemont, Illinois, 60439
Loma Linda University Health
Loma Linda, California, 92354
University of California Los Angeles
Los Angeles, California, 90095
Georgia Retina PC
Marietta, Georgia, 30060
Florida Eye Associates
Melbourne, Florida, 32901
Vitreoretinal Surgery PA
Minneapolis, Minnesota, 55435
Northern California Retina Vitreous Associates
Mountain View, California, 94040
Tennessee Retina
Nashville, Tennessee, 37203
Vitreous Retina Macula Consultants of NY
New York, New York, 10022
Retina Institute of California
Palm Desert, California, 92260
California Eye Specialists
Pasadena, California, 91107
Retina Specialty Institute
Pensacola, Florida, 32503
Retinovitreous Associates
Philadelphia, Pennsylvania, 19107
Associated Retina Consultants
Phoenix, Arizona, 85020
Retina Consultants San Diego
Poway, California, 92064
Black Hills Regional Eye Institute
Rapid City, South Dakota, 57701
Sierra Eye Associates
Reno, Nevada, 89502
Associated Retina Consultants PC
Royal Oak, Michigan, 48073
Retinal Consultants Medical Group Inc
Sacramento, California, 95841
University of California San Francisco
San Francisco, California, 94143
Orange County Retina Medical Group
Santa Ana, California, 92705
California Retina Consultants
Santa Barbara, California, 93103
Retina Associates, PA
Shawnee Mission, Kansas, 66204
Deep Blue Retina Clinical Research
Southaven, Mississippi, 38671
Spokane Eye Clinical Research
Spokane, Washington, 99204
Cascade Medical Research Institute
Springfield, Oregon, 97477
Southern Vitreoretinal Associates
Tallahassee, Florida, 32308
Retina Vitreous Associates of Florida
Tampa, Florida, 33607
Retina Consultants of Houston
The Woodlands, Texas, 77384
Associated Retina Consultants PC
Traverse City, Michigan, 49686
Albany Troy Cataract & Laser Associates
Troy, New York, 12180
New England Retina Associates PC
Waterford, Connecticut, 06385
Strategic Clinical Research Group, LLC
Willow Park, Texas, 76087
About this study
Official title: A Phase 2 Multicenter, Randomized, Double-Masked, Sham-Controlled Study of the Safety and Efficacy of Intravitreal Injections of NGM621 in Subjects With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
This is a multi-center evaluation of NGM621 in a randomized, double-masked, sham-controlled study in participants with Geographic Atrophy secondary to Age-related Macular Degeneration.
- Conditions
- Geographic Atrophy
- Being tested
- NGM621, Sham Comparator
- Medical subject headings
- Geographic Atrophy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
NGM621Biological
NGM621 Dose 1
NGM621Biological
NGM621 Dose 2
Sham ComparatorOther
Sham Comparator
| Study group | Role | What they receive |
|---|---|---|
| NGM621 Treatment Group A (every 4 weeks) | Experimental | NGM621 single intravitreal (IVT) injection Receives: Biological: NGM621 |
| NGM621 Treatment Group C (every 8 weeks) | Experimental | NGM621 single IVT injection Receives: Biological: NGM621 |
| Sham Group B (every 4 weeks) | Sham comparator | Sham single IVT injection Receives: Other: Sham Comparator |
| Sham Group D (every 8 weeks) | Sham comparator | Sham single IVT injection Receives: Other: Sham Comparator |
What is being measured
The primary outcome is the main question the study is designed to answer.
The Rate of Change From Baseline in Geographic Atrophy (GA) Lesion Area
The rate of change from baseline in GA lesion area was measured by a non-invasive imaging technique called fundus autofluorescence (FAF) over the 52 weeks of treatment. FAF refers to the spontaneous emission of light by certain substances within the eye when exposed to a specific wavelength of light and involves quantifying the area and progression of atrophic lesions. The minimal GA lesion area is zero, the maximal GA lesion area is unknown. The higher the GA lesion area, the worse the visual outcome.
Measured: Baseline to Week 52
Number of Participants With Ocular Treatment-emergent Adverse Events in the Study Eye
A treatment-emergent adverse event (TEAE) was an adverse event (AE) that occurred during or after the first dose of study treatment.
Measured: Baseline to end of study (Week 56)
Secondary outcomes (12)
The Change From Baseline in Geographic Atrophy (GA) Lesion Area
Geographic atrophy lesion area was measured by a non-invasive imaging technique called fundus autofluorescence (FAF). FAF refers to the spontaneous emission of light by certain substances within the eye when exposed to a specific wavelength of light and involves quantifying the area and progression of atrophic lesions. The minimal GA lesion area is zero, the maximal GA lesion area is unknown. The higher the GA lesion area, the worse the visual outcome.
Measured: Baseline up to Week 52
The Rate of Change From Baseline in the Square Root of Geographic Atropy (GA) Lesion Area
Geographic atrophy lesion area was measured by fundus autofluorescence (FAF). FAF refers to the spontaneous emission of light by certain substances within the eye when exposed to a specific wavelength of light and involves quantifying the area and progression of atrophic lesions.
Measured: Baseline up to Week 52
The Change From Baseline in Best Corrected Visual Acuity Score
Best Corrected Visual Acuity Score is the best possible vision an eye can achieve with corrective lenses, typically glasses or contact lenses. BCVA was assessed by the Early Treatment of Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. ETDRS letter score is calculated when >20 letters are read correctly at 4.0 meters; the visual acuity letter score is equal to the total number of letters read correctly at 4.0 meters plus 30. If <20 letters are read correctly at 4.0 meters, the visual acuity letter score is equal to the total number of letters read correctly at 4.0 meters (number of letters recorded on line 1.0), plus the total number of letters in the first six lines read correctly at 1.0 meter. Therefore, the ETDRS letter score could result in a score of 0-100, where lower scores indicate better vision.
The change from baseline in BCVA is being report with negative scores indicating an improvement in vision.
Measured: Baseline up to Week 52
The Change From Baseline in Low Luminance Visual Acuity Score
Low Luminance Visual Acuity Score measures vision in low-light conditions. It was assessed by the Early Treatment of Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters.
ETDRS letter score is calculated when >20 letters are read correctly at 4.0 meters; the visual acuity letter score is equal to the total number of letters read correctly at 4.0 meters plus 30. If <20 letters are read correctly at 4.0 meters, the visual acuity letter score is equal to the total number of letters read correctly at 4.0 meters (number of letters recorded on line 1.0), plus the total number of letters in the first six lines read correctly at 1.0 meter. Therefore, the ETDRS letter score could result in a score of 0-100, where lower scores indicate better vision.
A lower (negative) LLVA score compared to baseline indicates a decline in visual acuity. A higher (positive) LLVA score compared to baseline indicates an improvement in visual acuity.
Measured: Baseline up to Week 52
The Change From Baseline in Low Luminance Deficit Score
Low Luminance Deficit (LLD) Score was assessed by the Early Treatment of Diabetic Retinopathy Study (ETDRS) letters at a starting distance of 4 meters. ETDRS letter score is calculated when >20 letters are read correctly at 4.0 meters; the visual acuity letter score is equal to the total number of letters read correctly at 4.0 meters plus 30. If <20 letters are read correctly at 4.0 meters, the visual acuity letter score is equal to the total number of letters read correctly at 4.0 meters (number of letters recorded on line 1.0), plus the total number of letters in the first six lines read correctly at 1.0 meter. Therefore, the ETDRS letter score could result in a score of 0-100, where lower scores indicate better vision.
A LLD is the difference between standard visual acuity and LLVA, with a LLD >13 ETDRS letters suggesting potential visual abnormality. The change from baseline in LLD is being report with negative scores indicating an improvement in vision.
Measured: Baseline up to Week 52
The Change From Baseline in Average Binocular Reading Speed
Average binocular reading speed was assessed by Minnesota Low-Vision Reading Test (MNRead) or Radner reading charts. The change from baseline in average binocular reading speed is reported with a higher (positive) reading speed (wpm) indicates better reading ability, while a lower (negative) reading speed indicates poorer reading ability.
Measured: Baseline up to Week 52
The Change From Baseline in Binocular Critical Print Size
Binocular critical print size was assessed by the Minnesota Low-Vision Reading Test (MNRead) or Radner reading charts. MNRead uses a logarithmic scale (LogMAR) to represent print sizes, with each step representing a 0.1 LogMAR difference. The chart ranges from +1.3 LogMAR (equivalent to 20/400 at 40 cm) to -0.5 LogMAR (equivalent to 20/6 at 40 cm). The change from baseline in binocular critical print size is being reported with a higher (positive) LogMAR value for critical print size indicating that a person needs larger print sizes to maintain their maximum reading speed, while a lower (negative) LogMAR value indicates that they can read smaller print sizes at their maximum speed.
Measured: Baseline up to Week 52
The Change From Baseline in Binocular Reading Acuity
Binocular reading acuity was assessed by the Minnesota Low-Vision Reading Test (MNRead) or Radner reading charts. MNRead uses a logarithmic scale (LogMAR) to represent print sizes, with each step representing a 0.1 LogMAR difference. The chart ranges from +1.3 LogMAR (equivalent to 20/400 at 40 cm) to -0.5 LogMAR (equivalent to 20/6 at 40 cm). Binocular reading acuity is the smallest print size (in LogMAR) that a person can read easily and accurately. The change from baseline in binocular reading acuity is being reported with a higher LogMAR value for reading acuity indicates poorer reading ability, while a lower LogMAR value indicates better reading ability.
Measured: Baseline up to Week 52
The Change From Baseline in Functional Reading Independence Index Composite Score
The Functional Reading Independence (FRI) Index Composite Score is a 7-item patient questionnaire developed to evaluate the effect of geography atrophy on a patient's ability to independently perform reading activities. The FRI Index yields mean scores ranging from 1-4, with 1=unable to do and 4=totally independent. The FRI Index composite score is calculated by averaging the item-level scores across the seven questions, higher sores indicate better FRI. The change from baseline in FRI is being reported with lower (negative) values indicating a decline in FRI.
Measured: Baseline up to Week 52
The Change From Baseline in National Eye Institute Visual Functioning Questionnaire Composite Score
The National Eye Institute Visual Functioning Questionnaire Composite Score is calculated by averaging the scores of the 11 vision-targeted subscales, excluding the general health rating question, on a scale of 0 to 100, with higher scores indicating better vision-related function. The change from baseline is being reported with a negative value indicating a decline in vision function.
Measured: Baseline up to Week 52
The Change From Baseline in Systemic Complement Activity (CH50)
Systemic Complement Activity is a blood test that measures the overall activity of the complement system, a group of proteins crucial for the immune system's function. Low CH50 levels can be associated with certain infections. CH50 levels of 41 to 90 hemolytic units per mL (U/mL) is considered normal. The change from baseline in CH50 is being reported.
Measured: Baseline up to Week 52
Number of Anti-Drug Antibody (ADA)-Negative Participants
The incidence of anti-drug antibody (ADA) was assessed in serum.
Measured: Baseline up to Week 52
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Jul 2020
- Study start22 Jul 2020
- Primary completion16 Aug 2022
- Study completion16 Aug 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Geographic AtrophyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 320 participants (actual)
Sponsor and investigators
- Lead sponsor
- NGM Biopharmaceuticals, Inc
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- NGM Study Director, Study director, NGM Biopharmaceuticals
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04465955
- Sponsor's protocol ID
- 621-GA-201
- Acronym
- CATALINA
- Status last verified
- Jun 2025
- First submitted
- 1 Jul 2020
- Last updated
- 1 Jul 2025
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No: Since the study did not meet the study endpoints, there is no plan to make IPD available to other researchers.
Publications
Tzoumas N, Riding G, Williams MA, Steel DH. Complement inhibitors for age-related macular degeneration. Cochrane Database Syst Rev. 2023 Jun 14;6(6):CD009300. doi: 10.1002/14651858.CD009300.pub3.
PubMed 37314061
Study at a glance
From the registry record, last updated by the sponsor on 1 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 2 Multicenter, Randomized, Double-Masked, Sham-Controlled Study of the Safety and Efficacy of Intravitreal Injections of NGM621 in Subjects With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
- ClinicalTrials.gov ID
- NCT04465955
- Acronym / sponsor ID
- CATALINA / 621-GA-201
- Conditions
- Geographic Atrophy
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 320 participants (actual)
- Lead sponsor
- NGM Biopharmaceuticals, IncIndustry (pharma, biotech, devices)
- Study start
- 22 Jul 2020 (actual)
- Primary completion
- 16 Aug 2022 (actual)
- Study completion
- 16 Aug 2022 (actual)
- First posted
- 10 Jul 2020 (actual)
- Results
- Posted 1 Jul 2025
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a multi-center evaluation of NGM621 in a randomized, double-masked, sham-controlled study in participants with Geographic Atrophy secondary to Age-related Macular Degeneration.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| NGM621 Treatment Group A (every 4 weeks) | Experimental | Biological: NGM621NGM621 single intravitreal (IVT) injection |
| NGM621 Treatment Group C (every 8 weeks) | Experimental | Biological: NGM621NGM621 single IVT injection |
| Sham Group B (every 4 weeks) | Sham comparator | Other: Sham ComparatorSham single IVT injection |
| Sham Group D (every 8 weeks) | Sham comparator | Other: Sham ComparatorSham single IVT injection |
Who may qualify
- Ages
- 55 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Male or female (non-pregnant, non-lactating) subjects ≥ 55 years
- Standard luminance BCVA score of 34 letters or better using ETDRS charts at the starting distance of 4 meters (approximately 20/200 Snellen equivalent or better) in study eye
- Clinical diagnosis of GA secondary to AMD:
Key exclusion criteria (5 listed)
- Study Eye
- GA secondary to a condition other than AMD in either eye (e.g., monogenetic macular dystrophies like Stargardt disease, cone rod dystrophy, or toxic maculopathies)
- Any history of or active choroidal neovascularization (CNV)
- Both Eyes
- Any history of or active bacterial, viral, fungal, or parasitic infection in either eye in the 3 months prior to randomization
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| NGM621NGM621 Dose 1 | Biological | NGM621 Treatment Group A (every 4 weeks) |
| NGM621NGM621 Dose 2 | Biological | NGM621 Treatment Group C (every 8 weeks) |
| Sham ComparatorSham Comparator | Other | Sham Group B (every 4 weeks), Sham Group D (every 8 weeks) |
Primary outcome
The Rate of Change From Baseline in Geographic Atrophy (GA) Lesion Area
Time frame: Baseline to Week 52
The rate of change from baseline in GA lesion area was measured by a non-invasive imaging technique called fundus autofluorescence (FAF) over the 52 weeks of treatment. FAF refers to the spontaneous emission of light by certain substances within the eye when exposed to a specific wavelength of light and involves quantifying the area and progression of atrophic lesions. The minimal GA lesion area is zero, the maximal GA lesion area is unknown. The higher the GA lesion area, the worse the visual outcome.
Number of Participants With Ocular Treatment-emergent Adverse Events in the Study Eye
Time frame: Baseline to end of study (Week 56)
A treatment-emergent adverse event (TEAE) was an adverse event (AE) that occurred during or after the first dose of study treatment.
12 secondary outcomes
The Change From Baseline in Geographic Atrophy (GA) Lesion Area
Time frame: Baseline up to Week 52
The Rate of Change From Baseline in the Square Root of Geographic Atropy (GA) Lesion Area
Time frame: Baseline up to Week 52
The Change From Baseline in Best Corrected Visual Acuity Score
Time frame: Baseline up to Week 52
The Change From Baseline in Low Luminance Visual Acuity Score
Time frame: Baseline up to Week 52
The Change From Baseline in Low Luminance Deficit Score
Time frame: Baseline up to Week 52
The Change From Baseline in Average Binocular Reading Speed
Time frame: Baseline up to Week 52
The Change From Baseline in Binocular Critical Print Size
Time frame: Baseline up to Week 52
The Change From Baseline in Binocular Reading Acuity
Time frame: Baseline up to Week 52
The Change From Baseline in Functional Reading Independence Index Composite Score
Time frame: Baseline up to Week 52
The Change From Baseline in National Eye Institute Visual Functioning Questionnaire Composite Score
Time frame: Baseline up to Week 52
The Change From Baseline in Systemic Complement Activity (CH50)
Time frame: Baseline up to Week 52
Number of Anti-Drug Antibody (ADA)-Negative Participants
Time frame: Baseline up to Week 52
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Jul 2025.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 37314061Tzoumas N, Riding G, Williams MA, Steel DH. Complement inhibitors for age-related macular degeneration. Cochrane Database Syst Rev. 2023 Jun 14;6(6):CD009300. doi: 10.1002/14651858.CD009300.pub3.
- Individual participant dataSharing planned: No. Since the study did not meet the study endpoints, there is no plan to make IPD available to other researchers.
Related trials for Geographic Atrophy
Active, not recruitingPhase 1/2
Phase 1/2 Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
Age-Related Macular Degeneration, Geographic Atrophy
RecruitingPhase 1/2
Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration
Dry Age-Related Macular Degeneration, Geographic Atrophy
RecruitingPhase 3
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Age-related Macular Degeneration (AMD), Geographic Atrophy (GA)
RecruitingPhase 1
Phase 1 Study of C.001 in Retinal Degeneration
Geographic Atrophy, Stargardt Disease
RecruitingPhase 2/3
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
Geographic Atrophy, Macular Degeneration
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
NGM Study Director study director
NGM Biopharmaceuticals
65 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing NGM621 in people with Geographic Atrophy, run by NGM Biopharmaceuticals, Inc at 65 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 1 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 65 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 1 Jul 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The Rate of Change From Baseline in Geographic Atrophy (GA) Lesion Area (time frame: Baseline to Week 52). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04465955, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Jul 2025.